查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401926

到 2030 年全球標靶治療市場預測：按類型、癌症類型、給藥途徑、配銷通路、最終用戶和地區進行分析

Targeted Cancer Therapy Market Forecasts to 2030 - Global Analysis By Type, By Cancer Type, By Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球標靶癌症治療市場規模為 761 億美元，預計預測期內複合年成長率為 8.8%，到 2030 年將達到 1,374 億美元。

標靶癌症治療是一種精準醫學方法，使用藥物和其他物質來特異性識別和攻擊癌細胞，同時最大限度地減少對健康細胞的損害。這種方法旨在抑制癌細胞的生長和存活，並且通常比傳統化療具有更少的副作用。

據美國癌症協會稱，2019 年美國預計將診斷出約 170 萬新癌症病例。同樣，根據美國國家癌症研究所的數據，2018 年，美國約有 1,735,350 人新診斷出癌症，609,640 人死於癌症。

全球癌症發生率增加

人們越來越需要更有效、更有針對性的治療方法。標靶癌症治療精確地解決導致癌症進展的特定分子或遺傳異常，從而改善治療結果。各種癌症類型的負擔日益增加，加上對癌症遺傳基礎了解的進步，正在推動標靶治療的開發和採用。這一背景凸顯了開發創新和個體化治療方法的迫切需要，以及在面對癌症發病率不斷增加和多樣化的情況下，全球醫療保健迫切需要改善癌症治療和結果。符合要求。

與標靶治療相關的經濟負擔

雖然這些治療方法提供了準確有效的治療，但其高昂的成本往往會對負擔能力和可近性帶來挑戰。標靶抗癌藥物的研發和生產流程複雜，研究投入大，價格昂貴。此外，對持續監測、分子檢測和個體化治療計劃的需求增加了患者和醫療保健系統的總體經濟負擔。與標靶治療相關的費用可能會限制某些患者群體的獲得性治療，引發人們對醫療保健差異的擔憂。

癌症研究的支持政策與資金

世界各地的政府和醫療機構越來越認知到標靶治療徹底改變癌症治療的潛力。透過資金和支持政策促進研究、開發和臨床試驗的努力正在創造有利於創新的環境。此類財政支持加速了新型標靶治療的發現，加快了監管核准，並改善了市場准入。在雄厚資金的支持下，公私合作夥伴關係不僅能推動科學進步，還能確保前沿的標靶治療癌症治療更快地到達患者手中，解決未滿足的醫療需求，並為癌症治療的發展做出貢獻。

與標靶治療相關的副作用

儘管這些治療方法的目的是精確攻擊癌細胞，但脫靶效應和意想不到的後果可能會導致副作用。接受標靶治療的患者可能會出現疲勞、皮膚反應、胃腸道失調和免疫相關併發症等副作用。此外，標靶治療的潛在抗藥性和長期影響仍然令人擔憂。副作用不僅影響患者的生活品質，還可能導致治療中斷。

COVID-19 的影響：

COVID-19大流行對市場產生了重大影響。醫療保健系統的中斷、資源的重新優先排序以及臨床試驗的延遲正在阻礙標靶治療的開發和可用性。患者的焦慮和後勤的挑戰也影響著治療的醫囑遵從性。然而，這場大流行凸顯了創新治療方法的重要性，並加速了遠端醫療和數位健康解決方案在癌症護理中的採用。

乳癌領域預計在預測期內規模最大

乳癌領域預計將出現良好的成長。乳癌的標靶治療包括旨在解決特定分子特徵的藥物，例如 HER2 抑制劑和 CDK4/6 抑制劑。與傳統治療方法相比，這些治療方法副作用較少，療效也較高。乳癌標靶治療的進展凸顯了我們對個人化醫療的承諾，提供更個體化、更有效的治療選擇，特別是針對HER2陽性和荷爾蒙受體陽性乳癌亞型的患者，這就是我們所提供的。

預計醫院業在預測期內複合年成長率最高。

預計醫院產業在預測期內將以最快的複合年成長率成長。醫院為患者診斷、治療計劃和提供標靶治療提供關鍵基礎設施。醫院擁有專門的腫瘤科和多學科團隊，幫助患者獲得尖端的標靶癌症治療。此外，醫院正在為臨床試驗、合作研究和個體化癌症治療的整體進步做出貢獻，使其成為不斷發展的標靶治療介入領域的核心參與者。

佔有率最大的地區：

預計北美標靶癌症治療市場在預測期內將繼續佔據大部分市場佔有率。該地區強大的製藥業和支持性的法規環境促進了創新標靶治療的開發和採用。此外，學術界、研究機構和生物製藥公司之間的合作正在促進精準醫療方法的快速發展。北美仍然是臨床試驗的重要中心，推動個體化癌症治療的進步並影響標靶癌症治療的全球趨勢。

複合年成長率最高的地區：

預計亞太地區在預測期內複合年成長率最高。癌症發生率增加、醫療保健意識提高以及個人化醫療的進步等因素正在促進市場擴張。中國、日本和印度等國家正在進行緊張的研究和開發，以促進標靶治療的引入。亞太地區擁有完善的醫療基礎設施和完善的法規環境，使其成為創新標靶癌症治療的開發、商業化和採用的重要中心。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球標靶治療市場：按類型

  • 單株抗體
  • 利妥昔單抗
  • 低分子
  • 胺基酸
  • 免疫毒素
  • 白喉毒素 (DT)
  • 假單胞菌外毒素
  • 其他

第6章全球標靶治療市場：依癌症類型

  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 血癌
  • 婦科癌症
  • 其他

第7章全球標靶治療市場：依給藥途徑

  • 口服
  • 胃腸外的
  • 其他

第8章全球標靶治療市場：依配銷通路

  • 醫院藥房
  • 線上藥房
  • 零售藥房

第9章全球標靶治療市場：依最終用戶分類

  • 醫院
  • 癌症與放射治療中心
  • 專科診所
  • 其他

第10章全球標靶治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Abbott
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC.
  • Novartis AG
  • Aurobindo Pharma
  • Mirati Therapeutics, Inc
  • Bayer AG
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Hikma Pharmaceuticals PLC
  • ImmunoGen, Inc
Product Code: SMRC24446

According to Stratistics MRC, the Global Targeted Cancer Therapy Market is accounted for $76.1 billion in 2023 and is expected to reach $137.4 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Targeted cancer therapy is a precision medicine approach that involves using drugs or other substances to specifically identify and attack cancer cells while minimizing damage to healthy cells. This method aims to disrupt the growth and survival of cancer cells, often resulting in fewer side effects compared to traditional chemotherapy.

According to the American Cancer Society reports nearly 1.7 million new cancer cases are expected to be diagnosed in 2019 in the U.S. Similarly, according to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer were diagnosed in U.S. and 609,640 people died from the disease.

Market Dynamics:

Driver:

Increasing global cancer prevalence

There is a growing need for more effective and targeted treatment approaches. Targeted Cancer Therapy offers precision in addressing specific molecular and genetic aberrations driving cancer, leading to enhanced therapeutic outcomes. The rising burden of diverse cancer types, coupled with advancements in understanding the genetic basis of cancers, propels the development and adoption of targeted therapies. This driver underscores the urgency to develop innovative and personalized treatment options, aligning with the global healthcare imperative to improve cancer care and outcomes in the face of a rising and diverse cancer landscape.

Restraint:

Financial burden associated with targeted therapies

These therapies offer precise and effective treatments, their high costs often create challenges in terms of affordability and accessibility. The development and production of targeted cancer drugs involve complex processes and substantial research investments, leading to elevated pricing. Additionally, the need for ongoing monitoring, molecular testing, and personalized treatment plans contribute to the overall financial strain on patients and healthcare systems. The expense associated with targeted therapies may limit access for certain patient populations, raising concerns about healthcare disparities.

Opportunity:

Supportive policies and funding for cancer research

Governments and healthcare organizations worldwide are increasingly recognizing the potential of targeted therapies in revolutionizing cancer treatment. Initiatives that foster research, development, and clinical trials through funding and supportive policies create an environment conducive to innovation. This financial backing accelerates the discovery of novel targeted therapies, expedites regulatory approvals, and enhances market accessibility. The collaboration between public and private sectors, backed by robust funding, not only propels scientific advancements but also ensures that cutting-edge targeted cancer therapies can reach patients more swiftly, addressing unmet medical needs and contributing to the evolution of cancer care.

Threat:

Adverse effects associated with targeted therapies

While these therapies aim for precision in attacking cancer cells, off-target effects and unintended consequences may lead to adverse reactions. Patients undergoing targeted therapy may experience side effects such as fatigue, skin reactions, gastrointestinal issues, and immune-related complications. Additionally, the potential for resistance to targeted drugs and long-term effects remains a concern. Adverse effects not only impact the quality of life for patients but may also result in treatment discontinuation.

COVID-19 Impact:

The COVID-19 pandemic has significantly impacted the market. Disruptions in healthcare systems, reprioritization of resources, and delays in clinical trials have hindered the development and accessibility of targeted therapies. Patient concerns and logistical challenges have affected treatment adherence. However, the pandemic has underscored the importance of innovative therapies, accelerating the adoption of telemedicine and digital health solutions in cancer care.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is expected to have a lucrative growth. Targeted therapies for breast cancer include drugs like HER2 inhibitors and CDK4/6 inhibitors, aiming to address specific molecular characteristics. These therapies offer improved efficacy with fewer side effects compared to conventional treatments. The evolving landscape of targeted therapies for breast cancer underscores the commitment to personalized medicine, providing more tailored and effective treatment options for patients, particularly those with HER2-positive or hormone receptor-positive breast cancer subtypes.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. They provide a crucial infrastructure for patient diagnosis, treatment planning, and the delivery of targeted therapies. With specialized oncology departments and multidisciplinary teams, hospitals facilitate patient access to cutting-edge targeted cancer therapies. Additionally, hospitals contribute to clinical trials, research collaborations, and the overall advancement of personalized cancer care, making them central to the evolving landscape of targeted therapy interventions.

Region with largest share:

During the forecast period, it is expected that the North American Targeted Cancer Therapy market will continue to hold a majority of the market share. The region's robust pharmaceutical industry and supportive regulatory environment foster the development and adoption of innovative targeted therapies. Additionally, collaborations between academia, research institutions, and biopharmaceutical companies contribute to the rapid evolution of precision medicine approaches. North America continues to be a key hub for clinical trials, driving advancements in personalized cancer treatment and influencing global trends in the Targeted Cancer Therapy landscape.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. Factors such as increasing cancer incidence, rising healthcare awareness, and advancements in personalized medicine contribute to market expansion. Countries like China, Japan, and India are witnessing significant research and development activities, fostering the adoption of targeted therapies. The region's evolving healthcare infrastructure and supportive regulatory environments position Asia Pacific as a key hub for the development, commercialization, and adoption of innovative targeted cancer treatments.

Key players in the market:

Some of the key players in Targeted Cancer Therapy market include Abbott, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Novartis AG, Aurobindo Pharma, Mirati Therapeutics, Inc, Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Hikma Pharmaceuticals PLC and ImmunoGen, Inc.

Key Developments:

In July 2023, Genentech, Inc received approval from United States FDA for Tecentriq (atezolizumab) for adult and pediatric patients two years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).

In December 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) was approved in the United States for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.

Types Covered:

  • Monoclonal Antibodies
  • Rituximab
  • Small-Molecules
  • Amino Acids
  • Immunotoxins
  • Diphtheria toxin (DT)
  • Pseudomonas exotoxins
  • Other Types

Cancer Types Covered:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Blood Cancer
  • Gynecologic Cancer
  • Other Cancer Types

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Other Route of Administrations

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

End Users Covered:

  • Hospitals
  • Cancer and Radiation Therapy Centers
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Targeted Cancer Therapy Market, By Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
  • 5.3 Rituximab
  • 5.4 Small-Molecules
  • 5.5 Amino Acids
  • 5.6 Immunotoxins
  • 5.7 Diphtheria toxin (DT)
  • 5.8 Pseudomonas exotoxins
  • 5.9 Other Types

6 Global Targeted Cancer Therapy Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Lung Cancer
  • 6.3 Breast Cancer
  • 6.4 Colorectal Cancer
  • 6.5 Blood Cancer
  • 6.6 Gynecologic Cancer
  • 6.7 Other Cancer Types

7 Global Targeted Cancer Therapy Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Other Route of Administrations

8 Global Targeted Cancer Therapy Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacy
  • 8.3 Online Pharmacy
  • 8.4 Retail Pharmacy

9 Global Targeted Cancer Therapy Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Cancer and Radiation Therapy Centers
  • 9.4 Specialty Clinics
  • 9.5 Other End Users

10 Global Targeted Cancer Therapy Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott
  • 12.2 Pfizer Inc.
  • 12.3 Sun Pharmaceutical Industries Ltd.
  • 12.4 Amneal Pharmaceuticals LLC.
  • 12.5 Novartis AG
  • 12.6 Aurobindo Pharma
  • 12.7 Mirati Therapeutics, Inc
  • 12.8 Bayer AG
  • 12.9 Merck & Co. Inc.
  • 12.10 Bristol-Myers Squibb Company
  • 12.11 Cipla Inc.
  • 12.12 F. Hoffmann-La Roche Ltd
  • 12.13 GlaxoSmithKline plc
  • 12.14 Johnson & Johnson
  • 12.15 Hikma Pharmaceuticals PLC
  • 12.16 ImmunoGen, Inc

List of Tables

  • Table 1 Global Targeted Cancer Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Targeted Cancer Therapy Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 4 Global Targeted Cancer Therapy Market Outlook, By Rituximab (2021-2030) ($MN)
  • Table 5 Global Targeted Cancer Therapy Market Outlook, By Small-Molecules (2021-2030) ($MN)
  • Table 6 Global Targeted Cancer Therapy Market Outlook, By Amino Acids (2021-2030) ($MN)
  • Table 7 Global Targeted Cancer Therapy Market Outlook, By Immunotoxins (2021-2030) ($MN)
  • Table 8 Global Targeted Cancer Therapy Market Outlook, By Diphtheria toxin (DT) (2021-2030) ($MN)
  • Table 9 Global Targeted Cancer Therapy Market Outlook, By Pseudomonas exotoxins (2021-2030) ($MN)
  • Table 10 Global Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 11 Global Targeted Cancer Therapy Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 12 Global Targeted Cancer Therapy Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 13 Global Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 14 Global Targeted Cancer Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 15 Global Targeted Cancer Therapy Market Outlook, By Blood Cancer (2021-2030) ($MN)
  • Table 16 Global Targeted Cancer Therapy Market Outlook, By Gynecologic Cancer (2021-2030) ($MN)
  • Table 17 Global Targeted Cancer Therapy Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 18 Global Targeted Cancer Therapy Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 19 Global Targeted Cancer Therapy Market Outlook, By Oral (2021-2030) ($MN)
  • Table 20 Global Targeted Cancer Therapy Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 21 Global Targeted Cancer Therapy Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 22 Global Targeted Cancer Therapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 23 Global Targeted Cancer Therapy Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 24 Global Targeted Cancer Therapy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 25 Global Targeted Cancer Therapy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 26 Global Targeted Cancer Therapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Targeted Cancer Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Targeted Cancer Therapy Market Outlook, By Cancer and Radiation Therapy Centers (2021-2030) ($MN)
  • Table 29 Global Targeted Cancer Therapy Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 30 Global Targeted Cancer Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.